Alpha-1 Antitrypsin Deficiency Drug Enters Ph3 Trial
Grifols enrolled the first patient in its Phase 3 SWIFT-SC clinical trial to evaluate its subcutaneous Alpha1-Proteinase Inhibitor for the treatment of alpha1-antitrypsin (AAT) deficiency.
Grifols enrolled the first patient in its Phase 3 SWIFT-SC clinical trial to evaluate its subcutaneous Alpha1-Proteinase Inhibitor for the treatment of alpha1-antitrypsin (AAT) deficiency.
Researchers found that sialidase inhibitors—a class of flu drugs including oseltamivir (Tamiflu)—protected against degradation of protective sugar molecules tied to cognitive decline and premature aging in people living with HIV.
Read MoreResearchers found that five core values—safety, knowledge, trust, humanity, and autonomy—shape how minority parents approach pediatric vaccination.
Read MoreCombining formoterol and methacholine significantly improves mucociliary clearance in animal models of cystic fibrosis, compared to using either drug alone.
Read MoreResearchers at Adelaide University developed a lipid-polymer vehicle that improves drug bioavailability and reduces systemic toxicity in preclinical models of lung cancer.
Read MoreFor every 100 children vaccinated against influenza, between nine and 14 cases are prevented, according to Harvard Medical School data.
Read MoreUpdated clinical data demonstrates that Papzimeos for adults with Recurrent Respiratory Papillomatosis (RRP) can maintain complete responses for more than four years.
Read MoreResearchers developed an avian flu vaccine platform that generates immunity in the respiratory tract and bloodstream to combat H5N1.
Read MoreA study of over 1.1 million American adults with asthma found that Black, Hispanic, and Asian patients use ICS, LABA and LAMA inhalers less frequently than white patients.
Read MoreBenralizumab (Fasenra) is now indicated to reduce the risk of flare ups for adult and pediatric patients with hypereosinophilic syndrome.
Read MoreEnanta Pharmaceuticals will present data on its RSV therapy zelicapavir and on EPS-3903, an oral STAT6 inhibitor, at ATS 2026.
Read MoreData from clinical trials investigating treatments for pulmonary hypertension and pulmonary fibrosis will be highlighted at ATS 2026.
Read MorePhase 1 results for the inhaled drug candidate ALX1 focus on safety and pharmacokinetics for the treatment of serious lung diseases.
Read MoreThe once-weekly INNA-051 treatment from ENA Respiratory aims to prime the immune system to protect high-risk patients from influenza, RSV, and other respiratory viruses.
Read MoreThe COPD-OMA trial will examine if the asthma drug omalizumab (Xolair) benefits COPD patients with sensitivities to indoor allergens.
Read MoreThe MIRANDA study found tozorakimab significantly lowered the rate of moderate-to-severe respiratory worsening in patients regardless of smoking history or specific white blood cell counts.
Read MoreThe FDA is testing a new framework for monitoring safety signals as trials progress to reduce...
Read More